Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and compositions for the improvement of skeletal muscle function in a mammal

a skeletal muscle and composition technology, applied in the field of mammalian skeletal muscle function improvement methods and compositions, can solve the problems of no established clinical regimen for treating muscular dysfunction, and achieve the effects of reducing muscle fatigue, improving ability, and reducing muscle fatigu

Inactive Publication Date: 2013-08-22
VANDENBURGH HERMAN H +2
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes a method of treating cancer and increasing muscle strength by giving a low dosage of a biguanide or its derivative to a person. The treatment can result in a decrease in muscle fatigue and an increase in the ability to lift objects, participate in physical activity, and have reduced endurance limitations.

Problems solved by technology

However, there exists no established clinical regimen for treating muscular dysfunction.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for the improvement of skeletal muscle function in a mammal
  • Methods and compositions for the improvement of skeletal muscle function in a mammal
  • Methods and compositions for the improvement of skeletal muscle function in a mammal

Examples

Experimental program
Comparison scheme
Effect test

example 1

Metformin Increases Strength and Reduces the Fatigue Rate of Mouse Skeletal Muscle Tissue from a Genetic Model of Duchenne Muscular Dystrophy

[0115]Conditionally immortalized skeletal muscle cells from the mdx mouse muscle (Morgan et al., Dev Biol. 162: 486-498, 1994) were tissue engineered into contractile muscle tissue (mBAMs), as described herein. (See also, e.g., Vandenburgh et al., Muscle and Nerve 37: 438-447, 2008; Vandenburgh et al., Treat NMD Meeting, 2009). Briefly, several hundred thousand proliferating myoblasts were mixed with a solution of extracellular matrix (collagen or fibrin) and pipetted into custom wells containing two flexible “posts” (FIG. 1A). The cell / matrix mixture gelled around the tops of the posts, forming a defined tubular structure (FIG. 1B). The myoblasts differentiated into several hundred organized contractile muscle fibers (called miniature BioArtificial Muscle (mBAM); FIG. 1C) in tissue culture medium, such as that described in Vandenburgh et al., ...

example 2

Biguanides Increase Skeletal Muscle Strength and Decrease the Rate of Muscle Fatigue of Normal Mouse Skeletal Muscle Tissue

[0118]Skeletal muscle cells from the leg muscles of normal mice were isolated by standard tissue culture protocols (Rando et al., J Cell Biol. 125: 1275-1287, 1994), tissue engineered into contractile muscle tissue (mBAMs), and muscle force and fatigue measured as described in Example 1 (above).

[0119]High glucose tissue culture medium (4.5 g / l) was used in all experiments to maintain glucose levels well above normal human blood plasma levels (0.9 to 1.8 g / l) and, thereby, minimize drug action through increased glucose availability to the muscle cells. On Days 6-8 post-casting, metformin, phenformin (Fluka Cat. No. P7045-1G), or proguanil (Ipca Laboratories, CAS No. 637-32-1, Batch No. 8001HPRI) at different concentrations were added to the tissue culture medium, and maximal tetanic force was measured 24 hours later in a MFAS™. Every 24 hours, fresh metformin, ph...

example 3

Biguanides Increase Skeletal Muscle Strength and Reduce the Rate of Muscle Fatigue of Normal Human Muscle Tissue

[0123]Skeletal muscle cells from the vastus lateralis muscle of human volunteers were isolated by thin needle muscle biopsy and grown by standard tissue culture protocols (Shansky et al., “Tissue engineering human skeletal muscle for clinical applications” in Culture of Cells for Tissue Engineering (G. Vunjak and I. Freshney, eds.), pages 239-257, 2006), tissue engineered into contractile muscle tissue (mBAMs), and muscle force and fatigue measured as described in Example 1. On Days 7-10 post-casting, metformin, phenformin, buformin, or proguanil at different concentrations were added to the tissue culture medium and maximal tetanic force measured 24 hours later in MFAS™. High glucose tissue culture medium (4.5 g / l) was used to maintain glucose levels well above normal human blood plasma levels (0.9 to 1.8 g / l) and, thereby, minimize drug action through increased glucose a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Strengthaaaaaaaaaa
Login to View More

Abstract

The present invention is directed to the treatment of muscular dysfunction or increasing muscle strength and / or decreasing muscle fatigue in a subject using a composition that includes a biguanide or a pharmaceutically acceptable salt thereof, e.g., at a low dosage.

Description

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH[0001]This invention was made with government support under grant number NIH R44 NS059098. The government has certain rights in the invention.BACKGROUND OF THE INVENTION[0002]In general, the invention relates to methods of using a biguanide to treat muscular dysfunction, increase muscle strength, and / or reduce muscle fatigue. The invention also features pharmaceutical compositions formulated with low dosages of a biguanide.[0003]Progressive skeletal muscle weakness and fatigue accompany numerous human diseases and disorders including, e.g., cancer, acquired immune deficiency syndrome (AIDS), advanced organ failure (e.g., heart, liver, and kidney failure), chronic obstructive pulmonary disease (COPD), immobilization or disuse atrophy, burns, incontinence, sepsis, aging, and neuromuscular diseases (e.g., muscular dystrophies). Certain therapies may slow or reverse a decline in muscle mass or function including, e.g., hormonal interventions, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/155
CPCA61K31/155Y02A50/30
Inventor VANDENBURGH, HERMAN H.SHANSKY, JANET E.BENESCH-LEE, FRANK
Owner VANDENBURGH HERMAN H
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com